ArticleClinical and experimental immunology2008
Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.
Article in Clinical and experimental immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00074373 (The Research Registry for Neonatal Lupus), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Research Registry for Neonatal Lupus
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Geoepidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients’ dataTurkish journal of medical sciences · 2020Pooled it
- Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block.Arthritis and rheumatism · 2011Trial
- The pathogenic role of high-titer anti-Ro52 antibodies in neonatal lupus erythematosus: insights from a 9 case series.Frontiers in pediatrics · 2026Article
- An Overview of Neonatal Lupus with Anti-Ro Characteristics.International journal of molecular sciences · 2021Review
- Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus.Current opinion in rheumatology · 2017Review
- Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea-pigs.The Journal of physiology · 2016Article
- Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients.Lupus science & medicine · 2016Article
- In search of an antibody specificity highly predictive of congenital heart block.Lupus science & medicine · 2016Article
- The clinical spectrum of autoimmune congenital heart block.Nature reviews. Rheumatology · 2015Review
- Detection of autoantibodies in a point-of-care rheumatology setting.Auto- immunity highlights · 2013Review
- Article
- Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus.Arthritis care & research · 2012Article
- Congenital heart block: evidence for a pathogenic role of maternal autoantibodies.Arthritis research & therapy · 2012Review
- Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.Clinical reviews in allergy & immunology · 2011Review
- Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors.Arthritis and rheumatism · 2009Article
- Immune response against the coiled coil domain of Sjögren's syndrome associated autoantigen Ro52 induces salivary gland dysfunction.Clinical and experimental rheumatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Maternal autoantibodies to the p200-epitope of Ro52 have been suggested to correlate with development of congenital heart block. The aim of the present study was to evaluate the clinical relevance and predictive value of p200-antibodies in high-risk pregnancies. Sera from 515 Finnish, Swedish and American women were included in the study. Sera originated from 202 mothers with an infant affected by second- or third-degree atrioventricular block (AVB), 177 mothers with rheumatic disease having infants with normal heart rate and female blood donors (n = 136). A novel serological assay for Ro52 p200-antibodies with intra- and inter-assay variability of 3% and 3.8% respectively was developed. Mothers of children affected by AVB II-III had significantly higher p200-antibody levels than mothers with rheumatic disease having children with normal heart rate (P < 0.001). In the Swedish cohort, a distinction between foetuses with normal conduction, AVB I, AVB II and III was possible. A significant difference in anti-p200 levels between AVB I and AVB II-III groups compared with foetuses with normal conduction (P < 0.05 and P < 0.01) was observed. Using p200-antibodies as a second step analysis in Ro52-positive pregnancies increased the positive predictive value for foetal cardiac involvement (AVB I, II or III) from 0.39 (0.27-0.51) to 0.53 (0.37-0.68). In conclusion, Ro52 p200-antibodies may occur in women with unaffected children, but levels are significantly higher in mothers of children with congenital heart block and are suggested as a relevant marker in evaluating the risk for foetal AV block.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.